Drug treatment options for the 2019-new coronavirus (2019-nCoV).
Identifieur interne : 000825 ( Main/Exploration ); précédent : 000824; suivant : 000826Drug treatment options for the 2019-new coronavirus (2019-nCoV).
Auteurs : Hongzhou Lu [République populaire de Chine]Source :
- Bioscience trends [ 1881-7823 ] ; 2020.
Descripteurs français
- KwdFr :
- Alanine (analogues et dérivés), Alanine (usage thérapeutique), Antiviraux (usage thérapeutique), Association médicamenteuse, Découverte de médicament, Humains, Infections à coronavirus (traitement médicamenteux), Lopinavir (usage thérapeutique), Nucléosides (usage thérapeutique), Pneumopathie virale (traitement médicamenteux), Ribonucléotides (usage thérapeutique), Ritonavir (usage thérapeutique), Sialidase (antagonistes et inhibiteurs).
- MESH :
- analogues et dérivés : Alanine.
- antagonistes et inhibiteurs : Sialidase.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : Alanine, Antiviraux, Lopinavir, Nucléosides, Ribonucléotides, Ritonavir.
- Association médicamenteuse, Découverte de médicament, Humains.
English descriptors
- KwdEn :
- Alanine (analogs & derivatives), Alanine (therapeutic use), Antiviral Agents (therapeutic use), Betacoronavirus, Coronavirus Infections (drug therapy), Drug Combinations, Drug Discovery, Humans, Lopinavir (therapeutic use), Neuraminidase (antagonists & inhibitors), Nucleosides (therapeutic use), Pneumonia, Viral (drug therapy), Ribonucleotides (therapeutic use), Ritonavir (therapeutic use).
- MESH :
- chemical , analogs & derivatives : Alanine.
- chemical , antagonists & inhibitors : Neuraminidase.
- chemical , therapeutic use : Alanine, Antiviral Agents, Lopinavir, Nucleosides, Ribonucleotides, Ritonavir.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- Betacoronavirus, Drug Combinations, Drug Discovery, Humans.
Abstract
As of January 22, 2020, a total of 571 cases of the 2019-new coronavirus (2019-nCoV) have been reported in 25 provinces (districts and cities) in China. At present, there is no vaccine or antiviral treatment for human and animal coronavirus, so that identifying the drug treatment options as soon as possible is critical for the response to the 2019-nCoV outbreak. Three general methods, which include existing broad-spectrum antiviral drugs using standard assays, screening of a chemical library containing many existing compounds or databases, and the redevelopment of new specific drugs based on the genome and biophysical understanding of individual coronaviruses, are used to discover the potential antiviral treatment of human pathogen coronavirus. Lopinavir /Ritonavir, Nucleoside analogues, Neuraminidase inhibitors, Remdesivir, peptide (EK1), abidol, RNA synthesis inhibitors (such as TDF, 3TC), anti-inflammatory drugs (such as hormones and other molecules), Chinese traditional medicine, such ShuFengJieDu Capsules and Lianhuaqingwen Capsule, could be the drug treatment options for 2019-nCoV. However, the efficacy and safety of these drugs for 2019- nCoV still need to be further confirmed by clinical experiments.
DOI: 10.5582/bst.2020.01020
PubMed: 31996494
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000C28
- to stream PubMed, to step Curation: 000C28
- to stream PubMed, to step Checkpoint: 000767
- to stream Ncbi, to step Merge: 000928
- to stream Ncbi, to step Curation: 000928
- to stream Ncbi, to step Checkpoint: 000928
- to stream Main, to step Merge: 000827
- to stream Main, to step Curation: 000825
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Drug treatment options for the 2019-new coronavirus (2019-nCoV).</title><author><name sortKey="Lu, Hongzhou" sort="Lu, Hongzhou" uniqKey="Lu H" first="Hongzhou" last="Lu">Hongzhou Lu</name><affiliation wicri:level="1"><nlm:affiliation>Scientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Scientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:31996494</idno><idno type="pmid">31996494</idno><idno type="doi">10.5582/bst.2020.01020</idno><idno type="wicri:Area/PubMed/Corpus">000C28</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000C28</idno><idno type="wicri:Area/PubMed/Curation">000C28</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000C28</idno><idno type="wicri:Area/PubMed/Checkpoint">000767</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000767</idno><idno type="wicri:Area/Ncbi/Merge">000928</idno><idno type="wicri:Area/Ncbi/Curation">000928</idno><idno type="wicri:Area/Ncbi/Checkpoint">000928</idno><idno type="wicri:Area/Main/Merge">000827</idno><idno type="wicri:Area/Main/Curation">000825</idno><idno type="wicri:Area/Main/Exploration">000825</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Drug treatment options for the 2019-new coronavirus (2019-nCoV).</title><author><name sortKey="Lu, Hongzhou" sort="Lu, Hongzhou" uniqKey="Lu H" first="Hongzhou" last="Lu">Hongzhou Lu</name><affiliation wicri:level="1"><nlm:affiliation>Scientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Scientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author></analytic><series><title level="j">Bioscience trends</title><idno type="eISSN">1881-7823</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Alanine (analogs & derivatives)</term><term>Alanine (therapeutic use)</term><term>Antiviral Agents (therapeutic use)</term><term>Betacoronavirus</term><term>Coronavirus Infections (drug therapy)</term><term>Drug Combinations</term><term>Drug Discovery</term><term>Humans</term><term>Lopinavir (therapeutic use)</term><term>Neuraminidase (antagonists & inhibitors)</term><term>Nucleosides (therapeutic use)</term><term>Pneumonia, Viral (drug therapy)</term><term>Ribonucleotides (therapeutic use)</term><term>Ritonavir (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Alanine (analogues et dérivés)</term><term>Alanine (usage thérapeutique)</term><term>Antiviraux (usage thérapeutique)</term><term>Association médicamenteuse</term><term>Découverte de médicament</term><term>Humains</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Lopinavir (usage thérapeutique)</term><term>Nucléosides (usage thérapeutique)</term><term>Pneumopathie virale (traitement médicamenteux)</term><term>Ribonucléotides (usage thérapeutique)</term><term>Ritonavir (usage thérapeutique)</term><term>Sialidase (antagonistes et inhibiteurs)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Alanine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Neuraminidase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Alanine</term><term>Antiviral Agents</term><term>Lopinavir</term><term>Nucleosides</term><term>Ribonucleotides</term><term>Ritonavir</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Alanine</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Sialidase</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Alanine</term><term>Antiviraux</term><term>Lopinavir</term><term>Nucléosides</term><term>Ribonucléotides</term><term>Ritonavir</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term><term>Drug Combinations</term><term>Drug Discovery</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Association médicamenteuse</term><term>Découverte de médicament</term><term>Humains</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">As of January 22, 2020, a total of 571 cases of the 2019-new coronavirus (2019-nCoV) have been reported in 25 provinces (districts and cities) in China. At present, there is no vaccine or antiviral treatment for human and animal coronavirus, so that identifying the drug treatment options as soon as possible is critical for the response to the 2019-nCoV outbreak. Three general methods, which include existing broad-spectrum antiviral drugs using standard assays, screening of a chemical library containing many existing compounds or databases, and the redevelopment of new specific drugs based on the genome and biophysical understanding of individual coronaviruses, are used to discover the potential antiviral treatment of human pathogen coronavirus. Lopinavir /Ritonavir, Nucleoside analogues, Neuraminidase inhibitors, Remdesivir, peptide (EK1), abidol, RNA synthesis inhibitors (such as TDF, 3TC), anti-inflammatory drugs (such as hormones and other molecules), Chinese traditional medicine, such ShuFengJieDu Capsules and Lianhuaqingwen Capsule, could be the drug treatment options for 2019-nCoV. However, the efficacy and safety of these drugs for 2019- nCoV still need to be further confirmed by clinical experiments.</div></front></TEI><affiliations><list><country><li>République populaire de Chine</li></country></list><tree><country name="République populaire de Chine"><noRegion><name sortKey="Lu, Hongzhou" sort="Lu, Hongzhou" uniqKey="Lu H" first="Hongzhou" last="Lu">Hongzhou Lu</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000825 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000825 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:31996494
|texte= Drug treatment options for the 2019-new coronavirus (2019-nCoV).
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:31996494" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidV2
| This area was generated with Dilib version V0.6.33. |  |